Literature DB >> 15735927

Chronic inflammatory polyneuropathy revealing malignant melanoma.

A Rousseau, F Salachas, M Baccard, J Y Delattre, M Sanson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15735927     DOI： 10.1007/s11060-004-1871-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  9 in total

1.  Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

Authors:  M N Saleh; M B Khazaeli; R H Wheeler; E Dropcho; T Liu; M Urist; D M Miller; S Lawson; P Dixon; C H Russell
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Myelin-associated glycoprotein shares an antigenic determinant with a glycoprotein of human melanoma cells.

Authors:  A B Noronha; J R Harper; A A Ilyas; R A Reisfeld; R H Quarles
Journal:  J Neurochem       Date:  1986-11       Impact factor: 5.372

3.  Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy.

Authors:  N Yuki; M Yamada; Y Tagawa; H Takahashi; S Handa
Journal:  J Neurol Sci       Date:  1997-08       Impact factor: 3.181

4.  Demyelinating neuropathies triggered by melanoma immunotherapy.

Authors:  G N Fuller; J M Spies; J D Pollard; J G McLeod
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

Review 5.  Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma.

Authors:  D A Anthoney; I Bone; T R Evans
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

6.  Prolonged survival in metastatic malignant melanoma associated with vitiligo.

Authors:  P Duhra; A Ilchyshyn
Journal:  Clin Exp Dermatol       Date:  1991-07       Impact factor: 3.470

7.  Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma.

Authors:  M D Weiss; C A Luciano; C Semino-Mora; M C Dalakas; R H Quarles
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

8.  Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma.

Authors:  S J Bird; M J Brown; M E Shy; S S Scherer
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

9.  Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

Authors:  C Yee; J A Thompson; P Roche; D R Byrd; P P Lee; M Piepkorn; K Kenyon; M M Davis; S R Riddell; P D Greenberg
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307
  9 in total
  3 in total

1.  Chronic idiopathic demyelinating polyneuropathy (CIDP) associated with Kaposi's sarcoma.

Authors:  Yahya Celik; Nilda Turgut; Burhan Turgut; Gülsüm E Pamuk; Muzaffer Demir
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

2.  Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Authors:  José-Alberto Palma; Salvador Martín-Algarra
Journal:  J Neurooncol       Date:  2009-03-06       Impact factor: 4.130

3.  Limbic encephalitis following immunotherapy against metastatic malignant melanoma.

Authors:  Sharfaraz Salam; Timothy Lavin; Ayse Turan
Journal:  BMJ Case Rep       Date:  2016-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.